Abstract
Diffuse large B cell lymphoma (DLBCL), an aggressive cancer of the B cells, is the most common subtype of non-Hodgkin lymphoma (NHL) worldwide. In China, the cases of DLBCL increase yearly. C-X-C chemokine receptor 4 (CXCR4) has been implicated in the migration and trafficking of malignant B cells in several hematological malignancies, and only a few reports have been published on the role of CXCR4 in the metastasis of DLBCL. This review summarizes the relevant perspectives on the functional mechanism, prognostic significance, and therapeutic applications of the CXCL12/CXCR4 axis in DLBCL, in particular DLBCL with bone marrow involvement.
References
1.
Armitage
J
. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin’ lymphoma by the non-Hodgkin’ lymphoma classification project
. Blood
. 1997
;•••
:89
.0006-49712.
Kumar
V
, Abbas
A
, Fausto
N
, et al. Robbins and Cotran Pathologic Basis of Disease, Professional Edition
. Oxford
: Elsevier LTD
; 2009
. p. 607
.3.
Swerdlow
S
, Campo
E
, Harris
NL
. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
. Lyon, France
: IARC Press
; 2008
.4.
Friedberg
JW
, Fisher
RI
. Diffuse large B-cell lymphoma
. Hematol Oncol Clin North Am
. 2008
Oct
;22
(5
):941
–52
.
[PubMed]
0889-85885.
Wu
L
, Ehlin-Henriksson
B
, Zhou
X
, et al. EBV provides survival factors to EBV+ DLBCL lines and modulates cytokine induced specific chemotaxis in EBV+ DLBCL
. Immunology
. 2017
;152
(4
):562
–73
.
[PubMed]
0019-28056.
Hui
D
, Proctor
B
, Donaldson
J
, Shenkier
T
, Hoskins
P
, Klasa
R
, et al. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone
. Leuk Lymphoma
. 2010
Sep
;51
(9
):1658
–67
.
[PubMed]
1042-81947.
Cultrera
JL
, Dalia
SM
. Diffuse large B-cell lymphoma: current strategies and future directions
. Cancer Contr
. 2012
Jul
;19
(3
):204
–13
.
[PubMed]
1073-27488.
Friedberg
JW
. Relapsed/refractory diffuse large B-cell lymphoma
. Hematology (Am Soc Hematol Educ Program)
. 2011
;2011
(1
):498
–505
.
[PubMed]
1520-43919.
Cai
Q
, Westin
J
, Fu
K
, Desai
M
, Zhang
L
, Huang
H
, et al. Accelerated therapeutic progress in diffuse large B cell lymphoma
. Ann Hematol
. 2014
Apr
;93
(4
):541
–56
.
[PubMed]
0939-555510.
Alizadeh
AA
, Eisen
MB
, Davis
RE
, Ma
C
, Lossos
IS
, Rosenwald
A
, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
. Nature
. 2000
Feb
;403
(6769
):503
–11
.
[PubMed]
0028-083611.
Meyer
PN
, Fu
K
, Greiner
TC
, Smith
LM
, Delabie
J
, Gascoyne
RD
, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab
. J Clin Oncol
. 2011
Jan
;29
(2
):200
–7
.
[PubMed]
0732-183X12.
Hans
CP
, Weisenburger
DD
, Greiner
TC
, Gascoyne
RD
, Delabie
J
, Ott
G
, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
. Blood
. 2004
Jan
;103
(1
):275
–82
.
[PubMed]
0006-497113.
Swerdlow
SH
, Campo
E
, Pileri
SA
, Harris
NL
, Stein
H
, Siebert
R
, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms
. Blood
. 2016
May
;127
(20
):2375
–90
.
[PubMed]
0006-497114.
Schmitz
R
, Wright
GW
, Huang
DW
, Johnson
CA
, Phelan
JD
, Wang
JQ
, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
. N Engl J Med
. 2018
Apr
;378
(15
):1396
–407
.
[PubMed]
0028-479315.
Ghielmini
M
, Vitolo
U
, Kimby
E
, Montoto
S
, Walewski
J
, Pfreundschuh
M
, et al.; Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma
. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
. Ann Oncol
. 2013
Mar
;24
(3
):561
–76
.
[PubMed]
0923-753416.
Perry
AM
, Mitrovic
Z
, Chan
WC
. Biological prognostic markers in diffuse large B-cell lymphoma
. Cancer Contr
. 2012
Jul
;19
(3
):214
–26
.
[PubMed]
1073-274817.
Acosta-Rodrã¬Guez E V, Merino M C, Montes C L, et al: Cytokines and chemokines shaping the B-cell compartment. Cytokine Growth Factor Rev
2007
; 18(1): 73-83.18.
Zwirner
NW
, Domaica
CI
. Cytokine regulation of natural killer cell effector functions
. Biofactors
. 2010
Jul-Aug
;36
(4
):274
–88
.
[PubMed]
0951-643319.
Zlotnik
A
, Burkhardt
AM
, Homey
B
. Homeostatic chemokine receptors and organ-specific metastasis
. Nat Rev Immunol
. 2011
Aug
;11
(9
):597
–606
.
[PubMed]
1474-173320.
Fu
L
, Li
ZJ
, Yang
GL
, Zheng
JF
, Shi
QZ
, Chen
SJ
, et al. [RNAi-mediated Silencing of CXCR4 Inhibits the Adhesion, Invasion and Tumorigenicity of Acute Monocytic Leukemic Cell Line SHI-1]
. Zhongguo Shi Yan Xue Ye Xue Za Zhi
. 2015
Oct
;23
(5
):1286
–91
.
[PubMed]
1009-213721.
Chatterjee
S
, Behnam Azad
B
, Nimmagadda
S
. The intricate role of CXCR4 in cancer
. Adv Cancer Res
. 2014
;124
(2
):31
–82
.
[PubMed]
0065-230X22.
Zhao
H
, Guo
L
, Zhao
H
, Zhao
J
, Weng
H
, Zhao
B
. CXCR4 over-expression and survival in cancer: a system review and meta-analysis
. Oncotarget
. 2015
Mar
;6
(7
):5022
–40
.
[PubMed]
1949-255323.
Kallikourdis
M
, Trovato
AE
, Anselmi
F
, Sarukhan
A
, Roselli
G
, Tassone
L
, et al. The CXCR4 mutations in WHIM syndrome impair the stability of the T-cell immunologic synapse
. Blood
. 2013
Aug
;122
(5
):666
–73
.
[PubMed]
0006-497124.
Cojoc
M
, Peitzsch
C
, Trautmann
F
, Polishchuk
L
, Telegeev
GD
, Dubrovska
A
. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis
. Onco Targets Ther
. 2013
Sep
;6
:1347
–61
.
[PubMed]
1178-693025.
Katsura
M
, Shoji
F
, Okamoto
T
, Shimamatsu
S
, Hirai
F
, Toyokawa
G
, et al. Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph-node-positive lung cancer patients
. Cancer Sci
. 2018
Jan
;109
(1
):154
–65
.
[PubMed]
1347-903226.
Rasti
A
, Abolhasani
M
, Zanjani
LS
, Asgari
M
, Mehrazma
M
, Madjd
Z
. Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma
. J Cancer Res Clin Oncol
. 2017
Jan
;143
(1
):95
–104
.
[PubMed]
0171-521627.
Conley-LaComb
MK
, Semaan
L
, Singareddy
R
, Li
Y
, Heath
EI
, Kim
S
, et al. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis
. Mol Cancer
. 2016
Nov
;15
(1
):68
.
[PubMed]
1476-459828.
Chittasupho
C
, Anuchapreeda
S
, Sarisuta
N
. CXCR4 targeted dendrimer for anti-cancer drug delivery and breast cancer cell migration inhibition
. Eur J Pharm Biopharm
. 2017
Oct
;119
:310
–21
.
[PubMed]
0939-641129.
Weixler
B
, Renetseder
F
, Facile
I
, Tosti
N
, Cremonesi
E
, Tampakis
A
, et al. Phosphorylated CXCR4 expression has a positive prognostic impact in colorectal cancer
. Cell Oncol (Dordr)
. 2017
Dec
;40
(6
):609
–19
.
[PubMed]
2211-342830.
Kaemmerer
D
, Schindler
R
, Mußbach
F
, et al.: Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.
BMC Cancer. 2017
; 28: 17(1):896. 31.
Calandra
G
, Bridger
G
, Fricker
S
. CXCR4 in clinical hematology
. Curr Top Microbiol Immunol
. 2010
;341
:173
–91
.
[PubMed]
0070-217X32.
Sison
EA
, McIntyre
E
, Magoon
D
, Brown
P
. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML
. Mol Cancer Res
. 2013
Sep
;11
(9
):1004
–16
.
[PubMed]
1541-778633.
Chen
Y
, Jacamo
R
, Konopleva
M
, Garzon
R
, Croce
C
, Andreeff
M
. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia
. J Clin Invest
. 2013
Jun
;123
(6
):2395
–407
.
[PubMed]
0021-973834.
Brault
L
, Rovó
A
, Decker
S
, Dierks
C
, Tzankov
A
, Schwaller
J
. CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia
. Leukemia
. 2014
Mar
;28
(3
):566
–76
.
[PubMed]
0887-692435.
Ahn
JY
, Seo
K
, Weinberg
OK
, Arber
DA
. The prognostic value of CXCR4 in acute myeloid leukemia
. Appl Immunohistochem Mol Morphol
. 2013
Jan
;21
(1
):79
–84
.
[PubMed]
1533-405836.
de Lourdes Perim
A
, Amarante
MK
, Guembarovski
RL
, de Oliveira
CE
, Watanabe
MA
. CXCL12/CXCR4 axis in the pathogenesis of acute lymphoblastic leukemia (ALL): a possible therapeutic target
. Cell Mol Life Sci
. 2015
May
;72
(9
):1715
–23
.
[PubMed]
1420-682X37.
Zhang
Y
, Guo
Q
, Zhao
H
, Zhao
D
, Wu
X
, Zhao
W
, et al. Expression of CXCR4 is an independent prognostic factor for overall survival and progression-free survival in patients with myelodysplastic syndrome
. Med Oncol
. 2013
Mar
;30
(1
):341
.
[PubMed]
1357-056038.
Schmidt
J
, Federmann
B
, Schindler
N
, Steinhilber
J
, Bonzheim
I
, Fend
F
, et al. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity
. Br J Haematol
. 2015
Jun
;169
(6
):795
–803
.
[PubMed]
0007-104839.
Han
TT
, Fan
L
, Li
JY
, Xu
W
. Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy
. Cancer Biol Ther
. 2014
Jan
;15
(1
):3
–9
.
[PubMed]
1538-404740.
Middle
S
, Coupland
SE
, Taktak
A
, Kidgell
V
, Slupsky
JR
, Pettitt
AR
, et al. Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin’s lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins
. Exp Hematol Oncol
. 2015
Apr
;4
(1
):10
.
[PubMed]
2162-361941.
Kim
YR
, Eom
KS
. Simultaneous inhibition of CXCR4 and VLA-4 exhibits combinatorial effect in overcoming stroma-mediated chemotherapy resistance in mantle cell lymphoma cells
. Immune Netw
. 2014
Dec
;14
(6
):296
–306
.
[PubMed]
1598-262942.
Zeng
Z
, Shi
YX
, Samudio
IJ
, Wang
RY
, Ling
X
, Frolova
O
, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
. Blood
. 2009
Jun
;113
(24
):6215
–24
.
[PubMed]
0006-497143.
Ko
SY
, Park
CJ
, Park
SH
, Cho
YU
, Jang
S
, Seo
EJ
, et al. High CXCR4 and low VLA-4 expression predicts poor survival in adults with acute lymphoblastic leukemia
. Leuk Res
. 2014
Jan
;38
(1
):65
–70
.
[PubMed]
0145-212644.
Lemma
SA
, Pasanen
AK
, Haapasaari
KM
, Sippola
A
, Sormunen
R
, Soini
Y
, et al. Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study
. Eur J Haematol
. 2016
May
;96
(5
):492
–501
.
[PubMed]
0902-444145.
Jahnke
K
, Coupland
SE
, Na
IK
, Loddenkemper
C
, Keilholz
U
, Korfel
A
, et al. Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma
. Blood
. 2005
Jul
;106
(1
):384
–5
.
[PubMed]
0006-497146.
Roy
I
, Evans
DB
, Dwinell
MB
. Chemokines and chemokine receptors: update on utility and challenges for the clinician
. Surgery
. 2014
Jun
;155
(6
):961
–73
.
[PubMed]
0039-606047.
Menter
T
, Ernst
M
, Drachneris
J
, Dirnhofer
S
, Barghorn
A
, Went
P
, et al. Phenotype profiling of primary testicular diffuse large B-cell lymphomas
. Hematol Oncol
. 2014
Jun
;32
(2
):72
–81
.
[PubMed]
0278-023248.
Moreno
MJ
, Bosch
R
, Dieguez-Gonzalez
R
, Novelli
S
, Mozos
A
, Gallardo
A
, et al. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival
. J Pathol
. 2015
Feb
;235
(3
):445
–55
.
[PubMed]
0022-341749.
Chen
J
, Xu-Monette
ZY
, Deng
L
, Shen
Q
, Manyam
GC
, Martinez-Lopez
A
, et al. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma
. Oncotarget
. 2015
Mar
;6
(8
):5597
–614
.
[PubMed]
1949-255350.
Shin
HC
, Seo
J
, Kang
BW
, Moon
JH
, Chae
YS
, Lee
SJ
, et al. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy
. Korean J Intern Med (Korean Assoc Intern Med)
. 2014
Nov
;29
(6
):785
–92
.
[PubMed]
1226-330351.
Stein
JV
, Nombela-Arrieta
C
. Chemokine control of lymphocyte trafficking: a general overview
. Immunology
. 2005
Sep
;116
(1
):1
–12
.
[PubMed]
0019-280552.
Deutsch
AJ
, Steinbauer
E
, Hofmann
NA
, Strunk
D
, Gerlza
T
, Beham-Schmid
C
, et al. Chemokine receptors in gastric MALT lymphoma: loss of CXCR4 and upregulation of CXCR7 is associated with progression to diffuse large B-cell lymphoma
. Mod Pathol
. 2013
Feb
;26
(2
):182
–94
.
[PubMed]
0893-395253.
Mazur
G
, Butrym
A
, Kryczek
I
, Dlubek
D
, Jaskula
E
, Lange
A
, et al. Decreased expression of CXCR4 chemokine receptor in bone marrow after chemotherapy in patients with non-Hodgkin lymphomas is a good prognostic factor
. PLoS One
. 2014
May
;9
(5
):e98194
.
[PubMed]
1932-620354.
Burger
JA
, Kipps
TJ
. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment
. Blood
. 2006
Mar
;107
(5
):1761
–7
.
[PubMed]
0006-497155.
Azab
AK
, Runnels
JM
, Pitsillides
C
, Moreau
AS
, Azab
F
, Leleu
X
, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
. Blood
. 2009
Apr
;113
(18
):4341
–51
.
[PubMed]
0006-497156.
Kurtova
AV
, Tamayo
AT
, Ford
RJ
, Burger
JA
. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting
. Blood
. 2009
May
;113
(19
):4604
–13
.
[PubMed]
0006-497157.
Coupland
SE
. The challenge of the microenvironment in B-cell lymphomas
. Histopathology
. 2011
Jan
;58
(1
):69
–80
.
[PubMed]
0309-016758.
Busillo
JM
, Benovic
JL
. Regulation of CXCR4 signaling
. Biochim Biophys Acta
. 2007
Apr
;1768
(4
):952
–63
.
[PubMed]
0006-300259.
Majchrzak
A
, Witkowska
M
, Smolewski
P
. Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance
. Molecules
. 2014
Sep
;19
(9
):14304
–15
.
[PubMed]
1420-304960.
Xu
ZZ
, Shen
JK
, Zhao
SQ
, et al. Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma
. [J]
. Leuk Lymphoma
. 2017
;•••
:1
–10
.
[PubMed]
1042-819461.
Wang
Y
, Zhang
M
, Xu
H
, Wang
Y
, Li
Z
, Chang
Y
, et al. Discovery and validation of the tumor-suppressive function of long noncoding RNA PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPK/ERK signaling pathway
. Oncotarget
. 2017
Aug
;8
(42
):72182
–96
.
[PubMed]
1949-255362.
Xu
ZZ
, Xia
ZG
, Wang
AH
, Wang
WF
, Liu
ZY
, Chen
LY
, et al. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab
. Ann Hematol
. 2013
Oct
;92
(10
):1351
–8
.
[PubMed]
0939-555563.
Camicia
R
, Winkler
HC
, Hassa
PO
. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review
. Mol Cancer
. 2015
Dec
;14
(1
):207
.
[PubMed]
1476-459864.
Peng
SB
, Peek
V
, Zhai
Y
, Paul
DC
, Lou
Q
, Xia
X
, et al. Akt activation, but not extracellular signal-regulated kinase activation, is required for SDF-1alpha/CXCR4-mediated migration of epitheloid carcinoma cells
. Mol Cancer Res
. 2005
Apr
;3
(4
):227
–36
.
[PubMed]
1541-778665.
Han
Y
, He
T
, Huang
DR
, Pardo
CA
, Ransohoff
RM
. TNF-alpha mediates SDF-1 alpha-induced NF-kappa B activation and cytotoxic effects in primary astrocytes
. J Clin Invest
. 2001
Aug
;108
(3
):425
–35
.
[PubMed]
0021-973866.
Mehta
SA
, Christopherson
KW
, Bhat-Nakshatri
P
, Goulet
RJ
Jr, Broxmeyer
HE
, Kopelovich
L
, et al. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion
. Oncogene
. 2007
May
;26
(23
):3329
–37
.
[PubMed]
0950-923267.
Yoshida
N
, Kitayama
D
, Arima
M
, Sakamoto
A
, Inamine
A
, Watanabe-Takano
H
, et al. CXCR4 expression on activated B cells is downregulated by CD63 and IL-21
. J Immunol
. 2011
Mar
;186
(5
):2800
–8
.
[PubMed]
0022-176768.
Brühl
H
, Cohen
CD
, Linder
S
, Kretzler
M
, Schlöndorff
D
, Mack
M
. Post-translational and cell type-specific regulation of CXCR4 expression by cytokines
. Eur J Immunol
. 2003
Nov
;33
(11
):3028
–37
.
[PubMed]
0014-298069.
Okera
M
, Bae
K
, Bernstein
E
, Cheng
L
, Lawton
C
, Wolkov
H
, et al. Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610
. BJU Int
. 2011
Jul
;108
(2 Pt 2
):E51
–8
.
[PubMed]
1464-409670.
Lenz
G
. Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications
. Cancers (Basel)
. 2015
May
;7
(2
):811
–22
.
[PubMed]
2072-669471.
Es-Haghi
M
, Soltanian
S
, Dehghani
H
. Perspective: cooperation of Nanog, NF-κΒ, and CXCR4 in a regulatory network for directed migration of cancer stem cells
. Tumour Biol
. 2016
Feb
;37
(2
):1559
–65
.
[PubMed]
1010-428372.
Young
KH
, Medeiros
LJ
, Chan
WC
. Diffuse large B-cell lymphoma. In: Orazi
A
, Weiss
LM
, Foucar
K
, Knowles
DM
, editors. Neoplastic Hematopathology
. Philadelphia, PA, USA
: Lippincott Willaims & Wilkins
; 2014
. pp. 502
–65
.73.
Förster
R
, Schubel
A
, Breitfeld
D
, Kremmer
E
, Renner-Müller
I
, Wolf
E
, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs
. Cell
. 1999
Oct
;99
(1
):23
–33
.
[PubMed]
0092-867474.
Burger
JA
, Ford
RJ
. The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies
. Semin Cancer Biol
. 2011
Nov
;21
(5
):308
–12
.
[PubMed]
1044-579X75.
Kiaii
S
, Clear
AJ
, Ramsay
AG
, Davies
D
, Sangaralingam
A
, Lee
A
, et al. Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation
. J Clin Oncol
. 2013
Jul
;31
(21
):2654
–61
.
[PubMed]
0732-183X76.
Medina
DJ
, Goodell
L
, Glod
J
, Gélinas
C
, Rabson
AB
, Strair
RK
. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways
. Haematologica
. 2012
Aug
;97
(8
):1255
–63
.
[PubMed]
0390-607877.
Gopal
AK
, Kahl
BS
, de Vos
S
, Wagner-Johnston
ND
, Schuster
SJ
, Jurczak
WJ
, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma
. N Engl J Med
. 2014
Mar
;370
(11
):1008
–18
.
[PubMed]
0028-479378.
Advani
RH
, Buggy
JJ
, Sharman
JP
, Smith
SM
, Boyd
TE
, Grant
B
, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies
. J Clin Oncol
. 2013
Jan
;31
(1
):88
–94
.
[PubMed]
0732-183X79.
Wang
ML
, Rule
S
, Martin
P
, Goy
A
, Auer
R
, Kahl
BS
, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
. N Engl J Med
. 2013
Aug
;369
(6
):507
–16
.
[PubMed]
0028-479380.
Chang
BY
, Francesco
M
, De Rooij
MF
, Magadala
P
, Steggerda
SM
, Huang
MM
, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
. Blood
. 2013
Oct
;122
(14
):2412
–24
.
[PubMed]
0006-497181.
Beider
K
, Ribakovsky
E
, Abraham
M
, Wald
H
, Weiss
L
, Rosenberg
E
, et al. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140
. Clin Cancer Res
. 2013
Jul
;19
(13
):3495
–507
.
[PubMed]
1078-043282.
Vianello
F
, Villanova
F
, Tisato
V
, Lymperi
S
, Ho
KK
, Gomes
AR
, et al. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis
. Haematologica
. 2010
Jul
;95
(7
):1081
–9
.
[PubMed]
0390-607883.
Heckmann
D
, Maier
P
, Laufs
S
, Wenz
F
, Zeller
WJ
, Fruehauf
S
, et al. CXCR4 Expression and Treatment with SDF-1α or Plerixafor Modulate Proliferation and Chemosensitivity of Colon Cancer Cells
. Transl Oncol
. 2013
Apr
;6
(2
):124
–32
.
[PubMed]
1936-523384.
Domanska
UM
, Timmer-Bosscha
H
, Nagengast
WB
, Oude Munnink
TH
, Kruizinga
RC
, Ananias
HJ
, et al. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy
. Neoplasia
. 2012
Aug
;14
(8
):709
–18
.
[PubMed]
1522-800285.
Foon
KA
, Takeshita
K
, Zinzani
PL
. Novel therapies for aggressive B-cell lymphoma
. Adv Hematol
. 2012
;2012
:302570
.
[PubMed]
1687-910486.
Ramsey
DM
, McAlpine
SR
. Halting metastasis through CXCR4 inhibition
. Bioorg Med Chem Lett
. 2013
Jan
;23
(1
):20
–5
.
[PubMed]
0960-894X87.
O’Callaghan
K
, Lee
L
, Nguyen
N
, Hsieh
MY
, Kaneider
NC
, Klein
AK
, et al. Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia
. Blood
. 2012
Feb
;119
(7
):1717
–25
.
[PubMed]
0006-497188.
Hu
Y
, Gale
M
, Shields
J
, Garron
C
, Swistak
M
, Nguyen
TH
, et al. Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists
. Leuk Lymphoma
. 2012
Jan
;53
(1
):130
–8
.
[PubMed]
1042-819489.
Burger
JA
. Disrupting the food chain in B cell lymphomas: co-operation between CXCR4 antagonists and antibodies
. Leuk Lymphoma
. 2012
Jan
;53
(1
):3
–4
.
[PubMed]
1042-819490.
Reinholdt
L
, Laursen
MB
, Schmitz
A
, Bødker
JS
, Jakobsen
LH
, Bøgsted
M
, et al. The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines
. Biomark Res
. 2016
Jun
;4
(1
):12
.
[PubMed]
2050-777191.
Lee
CH
, Kakinuma
T
, Wang
J
, Zhang
H
, Palmer
DC
, Restifo
NP
, et al. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases
. Mol Cancer Ther
. 2006
Oct
;5
(10
):2592
–9
.
[PubMed]
1535-716392.
Welschinger
R
, Liedtke
F
, Basnett
J
, Dela Pena
A
, Juarez
JG
, Bradstock
KF
, et al. Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice
. Exp Hematol
. 2013
Mar
;41
(3
):293
–302.e1
.
[PubMed]
0301-472X93.
Chou
TC
. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
. Pharmacol Rev
. 2006
Sep
;58
(3
):621
–81
.
[PubMed]
0031-6997© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
